Reily C, Stewart TJ, Renfrow MB, Novak J. Glycosylation in health and disease. Nat Rev Nephrol. 2019;15:346–66.
Varki A, Kornfeld S. Historical background and overview. In: Varki A, Cummings RD, Esko J, Stanley P, Hart GW, Aebi M, et al. editors. Essentials of glycobiology. 4th ed. Chapter 1. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2022.
Fisher P, Thomas-Oates J, Wood AJ, Ungar D. The N-glycosylation processing potential of the mammalian Golgi apparatus. Front Cell Dev Biol. 2019;7:157.
Vosseller K, Wells L, Hart GW. Nucleocytoplasmic O-glycosylation: O-GlcNAc and functional proteomics. Biochimie. 2001;83:575–81.
Hart GW, Housley MP, Slawson C. Cycling of O-linked beta-N-acetylglucosamine on nucleocytoplasmic proteins. Nature. 2007;446:1017–22.
Wells L, Gao Y, Mahoney JA, Vosseller K, Chen C, Rosen A, et al. Dynamic O-glycosylation of nuclear and cytosolic proteins: further characterization of the nucleocytoplasmic β-n-acetylglucosaminidase, O-Glcnacase*. J Biol Chem. 2002;277:1755–61.
Mueller TM, Meador-Woodruff JH. Post-translational protein modifications in schizophrenia. npj Schizophr. 2020;6:5.
Moremen KW, Tiemeyer M, Nairn AV. Vertebrate protein glycosylation: diversity, synthesis and function. Nat Rev Mol Cell Biol. 2012;13:448–62.
Hart GW, Copeland RJ. Glycomics hits the big time. Cell. 2010;143:672–6.
Goreta SS, Dabelic S, Dumic J. Insights into complexity of congenital disorders of glycosylation. Biochem Med (Zagreb). 2012;22:156–70.
Verheijen J, Tahata S, Kozicz T, Witters P, Morava E. Therapeutic approaches in Congenital Disorders of Glycosylation (CDG) involving N-linked glycosylation: an update. Genet Med. 2020;22:268–79.
Lefeber DJ, Freeze HH, Steet R, Kinoshita T. Congenital disorders of glycosylation. In: Essentials of glycobiology. 4th ed. Chapter 45. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2022.
Paprocka J, Jezela-Stanek A, Tylki-Szymańska A, Grunewald S. Congenital disorders of glycosylation from a neurological perspective. Brain Sci. 2021;11:88.
Freeze HH, Eklund EA, Ng BG, Patterson MC. Neurology of inherited glycosylation disorders. Lancet Neurol. 2012;11:453–66.
Freeze HH. Genetic defects in the human glycome. Nat Rev Genet. 2006;7:537–51.
Altassan R, Péanne R, Jaeken J, Barone R, Bidet M, Borgel D, et al. International clinical guidelines for the management of phosphomannomutase 2-congenital disorders of glycosylation: diagnosis, treatment and follow up. J Inherit Metab Dis. 2019;42:5–28.
West CM, Malzl D, Hykollari A, Wilson IBH. Glycomics. Glycoproteomics, and glycogenomics: an inter-taxa evolutionary perspective. Mol Cell Proteom. 2021;20:100024.
Guo Y, Jia W, Yang J, Zhan X. Cancer glycomics offers potential biomarkers and therapeutic targets in the framework of 3P medicine. Front Endocrinol (Lausanne). 2022;13:970489.
Rudman N, Gornik O, Lauc G. Altered N-glycosylation profiles as potential biomarkers and drug targets in diabetes. FEBS Lett. 2019;593:1598–615.
Shinohara Y, Furukawa J-I, Miura Y. Glycome as biomarkers. In: General methods in biomarker research and their applications. Dordrecht, Netherlands: Springer; 2015. 111–40.
Peng W, Kobeissy F, Mondello S, Barsa C, Mechref Y. MS-based glycomics: an analytical tool to assess nervous system diseases. Front Neurosci. 2022;16:1000179.
Kobeissy F, Kobaisi A, Peng W, Barsa C, Goli M, Sibahi A, et al. Glycomic and glycoproteomic techniques in neurodegenerative disorders and neurotrauma: towards personalized markers. Cells. 2022;11:581.
Iqbal S, Ghanimi Fard M, Everest-Dass A, Packer NH, Parker LM. Understanding cellular glycan surfaces in the central nervous system. Biochem Soc Trans. 2019;47:89–100.
Bauer D, Haroutunian V, Meador-Woodruff JH, McCullumsmith RE. Abnormal glycosylation of EAAT1 and EAAT2 in prefrontal cortex of elderly patients with schizophrenia. Schizophr Res. 2010;117:92–8.
Hüttenrauch M, Ogorek I, Klafki H, Otto M, Stadelmann C, Weggen S, et al. Glycoprotein NMB: a novel Alzheimer’s disease associated marker expressed in a subset of activated microglia. Acta Neuropathol Commun. 2018;6:108.
García-Ayllón MS, Botella-López A, Cuchillo-Ibañez I, Rábano A, Andreasen N, Blennow K, et al. HNK-1 carrier glycoproteins are decreased in the Alzheimer’s disease brain. Mol Neurobiol. 2017;54:188–99.
Hartz AM, Zhong Y, Wolf A, LeVine H 3rd, Miller DS, Bauer B. Abeta40 Reduces P-glycoprotein at the blood–brain barrier through the ubiquitin–proteasome pathway. J Neurosci. 2016;36:1930–41.
Chai AB, Leung GKF, Callaghan R, Gelissen IC. P-glycoprotein: a role in the export of amyloid-beta in Alzheimer’s disease?. FEBS J. 2020;287:612–25.
Stanley P, Moremen KW, Lewis NE, Taniguchi N, Aebi M. N-Glycans. In: Essentials of glycobiology. 4th ed. Chapter 9. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2022.
Abou-Abbass H, Abou-El-Hassan H, Bahmad H, Zibara K, Zebian A, Youssef R, et al. Glycosylation and other PTMs alterations in neurodegenerative diseases: current status and future role in neurotrauma. Electrophoresis. 2016;37:1549–61.
de Diego V, Martínez-Monseny AF, Muchart J, Cuadras D, Montero R, Artuch R, et al. Longitudinal volumetric and 2D assessment of cerebellar atrophy in a large cohort of children with phosphomannomutase deficiency (PMM2-CDG). J Inherit Metab Dis. 2017;40:709–13.
Serrano NL, De Diego V, Cuadras D, Martinez Monseny AF, Velázquez-Fragua R, López L, et al. A quantitative assessment of the evolution of cerebellar syndrome in children with phosphomannomutase-deficiency (PMM2-CDG). Orphanet J Rare Dis. 2017;12:155.
Izquierdo-Serra M, Martínez-Monseny AF, López L, Carrillo-García J, Edo A, Ortigoza-Escobar JD, et al. Stroke-like episodes and cerebellar syndrome in phosphomannomutase deficiency (PMM2-CDG): evidence for hypoglycosylation-driven channelopathy. Int J Mol Sci. 2018;19:619.
Ferreira CR, Altassan R, Marques-Da-Silva D, Francisco R, Jaeken J, Morava E. Recognizable phenotypes in CDG. J Inherit Metab Dis. 2018;41:541–53.
Ng BG, Buckingham KJ, Raymond K, Kircher M, Turner EH, He M, et al. Mosaicism of the UDP-galactose transporter SLC35A2 causes a congenital disorder of glycosylation. Am J Hum Genet. 2013;92:632–6.
Kodera H, Nakamura K, Osaka H, Maegaki Y, Haginoya K, Mizumoto S, et al. De novo mutations in SLC35A2 encoding a UDP-galactose transporter cause early-onset epileptic encephalopathy. Hum Mutat. 2013;34:1708–14.
EuroEPINOMICS-RES Consortium; Epilepsy Phenome/Genome Project; Epi4K Consortium. De novo mutations in synaptic transmission genes including DNM1 cause epileptic encephalopathies. Am J Hum Genet. 2014;95:360–70.
Dörre K, Olczak M, Wada Y, Sosicka P, Grüneberg M, Reunert J, et al. A new case of UDP-galactose transporter deficiency (SLC35A2-CDG): molecular basis, clinical phenotype, and therapeutic approach. J Inherit Metab Dis. 2015;38:931–40.
Bosch DG, Boonstra FN, de Leeuw N, Pfundt R, Nillesen WM, de Ligt J, et al. Novel genetic causes for cerebral visual impairment. Eur J Hum Genet. 2016;24:660–5.
Lelieveld SH, Reijnders MR, Pfundt R, Yntema HG, Kamsteeg EJ, de Vries P, et al. Meta-analysis of 2,104 trios provides support for 10 new genes for intellectual disability. Nat Neurosci. 2016;19:1194–6.
Kimizu T, Takahashi Y, Oboshi T, Horino A, Koike T, Yoshitomi S, et al. A case of early onset epileptic encephalopathy with de novo mutation in SLC35A2: Clinical features and treatment for epilepsy. Brain Dev. 2017;39:256–60.
Bruneel A, Cholet S, Drouin-Garraud V, Jacquemont ML, Cano A, Mégarbané A, et al. Complementarity of electrophoretic, mass spectrometric, and gene sequencing techniques for the diagnosis and characterization of congenital disorders of glycosylation. Electrophoresis. 2018;39:3123–32.
Westenfield K, Sarafoglou K, Speltz LC, Pierpont EI, Steyermark J, Nascene D, et al. Mosaicism of the UDP-Galactose transporter SLC35A2 in a female causing a congenital disorder of glycosylation: a case report. BMC Med Genet. 2018;19:100.
Winawer MR, Griffin NG, Samanamud J, Baugh EH, Rathakrishnan D, Ramalingam S, et al. Somatic SLC35A2 variants in the brain are associated with intractable neocortical epilepsy. Ann Neurol. 2018;83:1133–46.
Yates TM, Suri M, Desurkar A, Lesca G, Wallgren-Pettersson C, Hammer TB, et al. SLC35A2-related congenital disorder of glycosylation: defining the phenotype. Eur J Paediatr Neurol. 2018;22:1095–102.
Sim NS, Seo Y, Lim JS, Kim WK, Son H, Kim HD, et al. Brain somatic mutations in SLC35A2 cause intractable epilepsy with aberrant N-glycosylation. Neurol Genet. 2018;4:e294.
Iqbal Z, Shahzad M, Vissers LE, van Scherpenzeel M, Gilissen C, Razzaq A, et al. A compound heterozygous mutation in DPAGT1 results in a congenital disorder of glycosylation with a relatively mild phenotype. Eur J Hum Genet. 2013;21:844–9.
Yuste-Checa P, Vega AI, Martín-Higueras C, Medrano C, Gámez A, Desviat LR, et al. DPAGT1-CDG: functional analysis of disease-causing pathogenic mutations and role of endoplasmic reticulum stress. PLoS ONE. 2017;12:e0179456.
Öncül Ü, Kose E, Eminoğlu FT. ALG1-CDG: a patient with a mild phenotype and literature review. Mol Syndromol. 2022;13:69–74.
Kamarus Jaman N, Rehsi P, Henderson RH, Löbel U, Mankad K, Grunewald S. SRD5A3-CDG: emerging phenotypic features of an ultrarare CDG subtype. Front Genet. 2021;12:737094.
Dwyer CA, Esko JD. Glycan susceptibility factors in autism spectrum disorders. Mol Asp Med. 2016;51:104–14.
Cast TP, Boesch DJ, Smyth K, Shaw AE, Ghebrial M, Chanda S. An autism-associated mutation impairs neuroligin-4 glycosylation and enhances excitatory synaptic transmission in human neurons. J Neurosci. 2021;41:392–407.
Barone R, Sturiale L, Fiumara A, Palmigiano A, Bua RO, Rizzo R, et al. CSF N-glycan profile reveals sialylation deficiency in a patient with GM2 gangliosidosis presenting as childhood disintegrative disorder. Autism Res. 2016;9:423–8.
Pivac N, Knezević A, Gornik O, Pucić M, Igl W, Peeters H, et al. Human plasma glycome in attention-deficit hyperactivity disorder and autism spectrum disorders. Mol Cell Proteom. 2011;10:M110.004200.
Kumar A, Sidhu J, Goyal A. Alzheimer disease. In: Tsao JW editor. StatPearls. Treasure Island, FL: StatPearls Publishing; 2022.
Conroy LR, Hawkinson TR, Young LEA, Gentry MS, Sun RC. Emerging roles of N-linked glycosylation in brain physiology and disorders. Trends Endocrinol Metab. 2021;32:980–93.
Cho BG, Veillon L, Mechref Y. N-Glycan profile of cerebrospinal fluids from Alzheimer’s disease patients using liquid chromatography with mass spectrometry. J Proteome Res. 2019;18:3770–9.
Vanoni O, Paganetti P, Molinari M. Consequences of individual N-glycan deletions and of proteasomal inhibition on secretion of active BACE. Mol Biol Cell. 2008;19:4086–98.
Kizuka Y, Kitazume S, Taniguchi N. N-glycan and Alzheimer’s disease. Biochim Biophys Acta—Gen Subj. 2017;1861:2447–54.
Schedin-Weiss S, Winblad B, Tjernberg LO. The role of protein glycosylation in Alzheimer disease. FEBS J. 2014;281:46–62.
Yu G, Nishimura M, Arawaka S, Levitan D, Zhang L, Tandon A, et al. Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and βAPP processing. Nature. 2000;407:48–54.
Arnold CS, Johnson GV, Cole RN, Dong DL, Lee M, Hart GW. The microtubule-associated protein tau is extensively modified with O-linked N-acetylglucosamine. J Biol Chem. 1996;271:28741–4.
Losev Y, Frenkel-Pinter M, Abu-Hussien M, Viswanathan GK, Elyashiv-Revivo D, Geries R, et al. Differential effects of putative N-glycosylation sites in human Tau on Alzheimer’s disease-related neurodegeneration. Cell Mol Life Sci. 2021;78:2231–45.
Zhang Q, Ma C, Chin LS, Li L. Integrative glycoproteomics reveals protein N-glycosylation aberrations and glycoproteomic network alterations in Alzheimer’s disease. Sci Adv. 2020;6:eabc5802.
Gizaw ST, Ohashi T, Tanaka M, Hinou H, Nishimura S. Glycoblotting method allows for rapid and efficient glycome profiling of human Alzheimer’s disease brain, serum and cerebrospinal fluid towards potential biomarker discovery. Biochim Biophys Acta. 2016;1860:1716–27.
Videira PAQ, Castro-Caldas M. Linking glycation and glycosylation with inflammation and mitochondrial dysfunction in Parkinson’s disease. Front Neurosci. 2018;12:381.
Jiang H, Jiang Q, Feng J. Parkin increases dopamine uptake by enhancing the cell surface expression of dopamine transporter *. J Biol Chem. 2004;279:54380–6.
Xu M, Jin H, Wu Z, Han Y, Chen J, Mao C, et al. Mass spectrometry-based analysis of serum N-glycosylation changes in patients with Parkinson’s disease. ACS Chem Neurosci. 2022;13:1719–26.
Lee SU, Grigorian A, Pawling J, Chen IJ, Gao G, Mozaffar T, et al. N-Glycan processing deficiency promotes spontaneous inflammatory demyelination and neurodegeneration*. J Biol Chem. 2007;282:33725–34.
Cvetko A, Kifer D, Gornik O, Klarić L, Visser E, Lauc G, et al. Glycosylation alterations in multiple sclerosis show increased proinflammatory potential. Biomedicines. 2020;8:410.
Rebelo AL, Chevalier MT, Russo L, Pandit A. Role and therapeutic implications of protein glycosylation in neuroinflammation. Trends Mol Med. 2022;28:270–89.
Patel KR, Cherian J, Gohil K, Atkinson D. Schizophrenia: overview and treatment options. P T. 2014;39:638–45.
Lavretsky H. History of schizophrenia as a psychiatric disorder. In Clinical handbook of schizophrenia. New York, NY, USA: The Guilford Press; 2008. 3–13.
Crismon M, Smith TL, Buckley PF. Schizophrenia. In: DiPiro JT, et al., editors. DiPiro’s pharmacotherapy: a pathophysiologic approach, 12e. New York, NY: McGraw Hill; 2023.
Beck AT, Rector NA, Stolar N, Grant P. Schizophrenia: cognitive theory, research, and therapy. New York, NY, USA: The Guilford Press; 2009, p. xiv, 418-xiv, 418.
Stanta JL, Saldova R, Struwe WB, Byrne JC, Leweke FM, Rothermund M, et al. Identification of N-glycosylation changes in the CSF and serum in patients with schizophrenia. J Proteome Res. 2010;9:4476–89.
Klarić TS, Lauc G. The dynamic brain N-glycome. Glycoconj J. 2022;39:443–71.
Tucholski J, Simmons MS, Pinner AL, Haroutunian V, McCullumsmith RE, Meador-Woodruff JH. Abnormal N-linked glycosylation of cortical AMPA receptor subunits in schizophrenia. Schizophr Res. 2013;146:177–83.
Williams SE, Mealer RG, Scolnick EM, Smoller JW, Cummings RD. Aberrant glycosylation in schizophrenia: a review of 25 years of post-mortem brain studies. Mol Psychiatry. 2020;25:3198–207.
Mueller TM, Haroutunian V, Meador-Woodruff JH. N-glycosylation of GABAA receptor subunits is altered in schizophrenia. Neuropsychopharmacology. 2014;39:528–37.
Mealer RG, Jenkins BG, Chen CY, Daly MJ, Ge T, Lehoux S, et al. The schizophrenia risk locus in SLC39A8 alters brain metal transport and plasma glycosylation. Sci Rep. 2020;10:13162.
Tudor L, Nedic Erjavec G, Nikolac Perkovic M, Konjevod M, Svob Strac D, et al. N-glycomic profile in combat related post-traumatic stress disorder. Biomolecules. 2019;9:834.
Fazekas CL, Sipos E, Klaric T, Török B, Bellardie M, Erjave GN, et al. Searching for glycomic biomarkers for predicting resilience and vulnerability in a rat model of posttraumatic stress disorder. Stress. 2020;23:715–31.
Boeck C, Pfister S, Bürkle A, Vanhooren V, Libert C, Salinas-Manrique J, et al. Alterations of the serum N-glycan profile in female patients with Major Depressive Disorder. J Affect Disord. 2018;234:139–47.
Park DI, Štambuk J, Razdorov G, Pučić-Baković M, Martins-de-Souza D, Lauc G, et al. Blood plasma/IgG N-glycome biosignatures associated with major depressive disorder symptom severity and the antidepressant response. Sci Rep. 2018;8:179.
Baysal BE, Willett-Brozick JE, Badner JA, Corona W, Ferrell RE, Nimgaonkar VL, et al. A mannosyltransferase gene at 11q23 is disrupted by a translocation breakpoint that co-segregates with bipolar affective disorder in a small family. Neurogenetics. 2002;4:43–53.
Brockhausen I, Wandall HH, Hagen KGT, Stanley P. O-GalNAc Glycans. In: Varki A, Cummings RD, Esko JD, et al., editors. Essentials of Glycobiology. 4th ed. Chapter 10. Cold Spring Harbor, NY; Cold Spring Harbor Laboratory Press; 2022.
van Tol W, Wessels H, Lefeber DJ. O-glycosylation disorders pave the road for understanding the complex human O-glycosylation machinery. Curr Opin Struct Biol. 2019;56:107–18.
Hennet T. Diseases of glycosylation beyond classical congenital disorders of glycosylation. Biochim Biophys Acta. 2012;1820:1306–17.
Scott K, Gadomski T, Kozicz T, Morava E. Congenital disorders of glycosylation: new defects and still counting. J Inherit Metab Dis. 2014;37:609–17.
Lipiński P, Tylki-Szymańska A. Congenital disorders of glycosylation: what clinicians need to know? Front Pediatr. 2021;9:715151.
Péanne R, de Lonlay P, Foulquier F, Kornak U, Lefeber DJ, Morava E, et al. Congenital disorders of glycosylation (CDG): Quo vadis?. Eur J Med Genet. 2018;61:643–63.
Zilmer M, Edmondson AC, Khetarpal SA, Alesi V, Zaki MS, Rostasy K, et al. Novel congenital disorder of O-linked glycosylation caused by GALNT2 loss of function. Brain. 2020;143:1114–26.
Nickolls AR, Bönneman CG. The roles of dystroglycan in the nervous system: insights from animal models of muscular dystrophy. Dis Model Mech. 2018;11:dmm035931.
Haukedal H, Freude KK. Implications of glycosylation in Alzheimer’s disease. Front Neurosci. 2021;14:625348.
Taniguchi K, Kobayashi K, Saito K, Yamanouchi H, Ohnuma A, Hayashi YK, et al. Worldwide distribution and broader clinical spectrum of muscle-eye-brain disease. Hum Mol Genet. 2003;12:527–34.
Zhang A, Venkat A, Taujale R, Mull JL, Ito A, Kannan N, et al. Peters plus syndrome mutations affect the function and stability of human β1,3-glucosyltransferase. J Biol Chem. 2021;297:100843.
Moll T, Shaw PJ, Cooper-Knock J. Disrupted glycosylation of lipids and proteins is a cause of neurodegeneration. Brain. 2019;143:1332–40.
Kobeissy F, Kobaisi A, Peng W, Barsa C, Goli M, Sibahi A, et al. Glycomic and glycoproteomic techniques in neurodegenerative disorders and neurotrauma: towards personalized markers. Cells. 2022;11:581.
Akasaka-Manya K, Manya H. The role of APP O-glycosylation in Alzheimer’s disease. Biomolecules. 2020;10:1569.
Akasaka-Manya K, Kawamura M, Tsumoto H, Saito Y, Tachida Y, Kitazume S, et al. Excess APP O-glycosylation by GalNAc-T6 decreases Aβ production. J Biochem. 2016;161:99–111.
Gizaw ST, Koda T, Amano M, Kamimura K, Ohashi T, Hinou H, et al. A comprehensive glycome profiling of Huntington’s disease transgenic mice. Biochim Biophys Acta. 2015;1850:1704–18.
Kanekiyo K, Inamori K, Kitazume S, Sato K, Maeda J, Higuchi M, et al. Loss of branched O-mannosyl glycans in astrocytes accelerates remyelination. J Neurosci. 2013;33:10037–47.
Rincón-Cortés M, Sullivan RM. Emergence of social behavior deficit, blunted corticolimbic activity and adult depression-like behavior in a rodent model of maternal maltreatment. Transl Psychiatry. 2016;6:e930.
Mealer RG, Williams SE, Daly MJ, Scolnick EM, Cummings RD, Smoller JW. Glycobiology and schizophrenia: a biological hypothesis emerging from genomic research. Mol psychiatry. 2020;25:3129–39.
Kato K, Hansen L, Clausen H. Polypeptide N-acetylgalactosaminyltransferase-associated phenotypes in mammals. Molecules. 2021;26:5504.
Newbury DF, Warburton PC, Wilson N, Bacchelli E, Carone S. International Molecular Genetic Study of Autism Consortium, et al. Mapping of partially overlapping de novo deletions across an autism susceptibility region (AUTS5) in two unrelated individuals affected by developmental delays with communication impairment. Am J Med Genet A. 2009;149a:588–97.
Milani D, Sabatini C, Manzoni FM, Ajmone PF, Rigamonti C, Malacarne M, et al. Microdeletion 2q23.3q24.1: exploring genotype-phenotype correlations. Congenit Anom (Kyoto). 2015;55:107–11.
Xu Y, Pang W, Lu J, Shan A, Zhang Y. Polypeptide N-acetylgalactosaminyltransferase 13 contributes to neurogenesis via stabilizing the mucin-type O-glycoprotein podoplanin. J Biol Chem. 2016;291:23477–88.
Mueller TM, Mallepalli NR, Meador-Woodruff JH. Altered protein expression of galactose and N-acetylgalactosamine transferases in schizophrenia superior temporal gyrus. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory; 2019.
Hori H, Sasayama D, Teraishi T, Yamamoto N, Nakamura S, Ota M, et al. Blood-based gene expression signatures of medication-free outpatients with major depressive disorder: integrative genome-wide and candidate gene analyses. Sci Rep. 2016;6:18776.
Gao L, Gao Y, Xu E, Xie J. Microarray Analysis of the Major Depressive Disorder mRNA Profile Data. Psychiatry Investig. 2015;12:388–96.
Zachara NE, Akimoto Y, Boyce M, Hart GW. The O-GlcNAc modification. Essentials of glycobiology. 4th ed. Chapter 19. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2022.
Matsuura A, Ito M, Sakaidani Y, Kondo T, Murakami K, Furukawa K, et al. O-linked N-acetylglucosamine is present on the extracellular domain of notch receptors. J Biol Chem. 2008;283:35486–95.
Sakaidani Y, Nomura T, Matsuura A, Ito M, Suzuki E, Murakami K, et al. O-linked-N-acetylglucosamine on extracellular protein domains mediates epithelial cell–matrix interactions. Nat Commun. 2011;2:583.
Varshney S, Stanley P. EOGT and O-GlcNAc on secreted and membrane proteins. Biochem Soc Trans. 2017;45:401–8.
Wani WY, Chatham JC, Darley-Usmar V, McMahon LL, Zhang J. O-GlcNAcylation and neurodegeneration. Brain Res Bull. 2017;133:80–87.
Trinidad JC, Barkan DT, Gulledge BF, Thalhammer A, Sali A, Schoepfer R, et al. Global identification and characterization of both O-GlcNAcylation and phosphorylation at the murine synapse. Mol Cell Proteom. 2012;11:215–29.
Schröder KC, Duman D, Tekin M, Schanze D, Sukalo M, Meester J, et al. Adams–Oliver syndrome caused by mutations of the EOGT gene. Am J Med Genet Part A. 2019;179:2246–51.
Fenckova M, Muha V, Mariappa D, Catinozzi M, Czajewski I, Blok LER, et al. Intellectual disability-associated disruption of O-GlcNAc cycling impairs habituation learning in Drosophila. PLoS Genet. 2022;18:e1010159.
Percy AK. Rett syndrome: exploring the autism link. Arch Neurol. 2011;68:985–9.
Neul JL. The relationship of Rett syndrome and MECP2 disorders to autism. Dialogues Clin Neurosci. 2012;14:253–62.
Cheng J, Zhao Z, Chen L, Li Y, Du R, Wu Y, et al. Loss of O-GlcNAcylation on MeCP2 at threonine 203 leads to neurodevelopmental disorders. Neurosci Bull. 2022;38:113–34.
Bertelli MO, Munir K, Harris J, Salvador-Carulla L. “Intellectual developmental disorders”: reflections on the international consensus document for redefining “mental retardation-intellectual disability” in ICD-11. Adv Ment Health Intellect Disabil. 2016;10:36–58.
Lee K, Cascella M, Marwaha R. Intellectual disability. In: StatPearls. Treasure Island, Fl: StatPearls Publishing; 2022.
Pravata VM, Omelková M, Stavridis MP, Desbiens CM, Stephen HM, Lefeber DJ, et al. An intellectual disability syndrome with single-nucleotide variants in O-GlcNAc transferase. Eur J Hum Genet. 2020;28:706–14.
Lee BE, Suh PG, Kim JI. O-GlcNAcylation in health and neurodegenerative diseases. Exp Mol Med. 2021;53:1674–82.
Haukedal H, Freude KK. Implications of glycosylation in Alzheimer’s disease. Front Neurosci. 2021;11:581.
Ma X, Li H, He Y, Hao J. The emerging link between O-GlcNAcylation and neurological disorders. Cell Mol Life Sci. 2017;74:3667–86.
Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron. 2004;43:321–32.
Cruz JC, Kim D, Moy LY, Dobbin MM, Sun X, Bronson RT, et al. p25/cyclin-dependent kinase 5 induces production and intraneuronal accumulation of amyloid beta in vivo. J Neurosci. 2006;26:10536–41.
Rajmohan R, Reddy PH. Amyloid-Beta and phosphorylated Tau accumulations cause abnormalities at synapses of Alzheimer’s disease neurons. J Alzheimers Dis. 2017;57:975–99.
Liu F, Iqbal K, Grundke-Iqbal I, Hart GW, Gong CX. O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer’s disease. Proc Natl Acad Sci USA. 2004;101:10804–9.
Wang AC, Jensen EH, Rexach JE, Vinters HV, Hsieh-Wilson LC. Loss of O -GlcNAc glycosylation in forebrain excitatory neurons induces neurodegeneration. Proc Natl Acad Sci USA. 2016;113:15120–5.
Park J, Ha HJ, Chung ES, Baek SH, Cho Y, Kim HK, et al. O-GlcNAcylation ameliorates the pathological manifestations of Alzheimer’s disease by inhibiting necroptosis. Sci Adv. 2021;7:eabd3207.
Permanne B, Sand A, Ousson S, Nény M, Hantson J, Schubert R, et al. O-GlcNAcase inhibitor ASN90 is a multimodal drug candidate for tau and α-synuclein proteinopathies. ACS Chem Neurosci. 2022;13:1296–314.
Marotta NP, Lin YH, Lewis YE, Ambroso MR, Zaro BW, Roth MT, et al. O-GlcNAc modification blocks the aggregation and toxicity of the protein alpha-synuclein associated with Parkinson’s disease. Nat Chem. 2015;7:913–20.
Ryan P, Xu MM, Davey AK, Kassiou M, Mellick GD, Rudrawar S. O-GlcNAcylation of truncated NAC segment alters peptide-dependent effects on α-synuclein aggregation. Bioorg Chem. 2020;94:103389.
Lee BE, Kim HY, Kim HJ, Jeong H, Kim BG, Lee HE, et al. O-GlcNAcylation regulates dopamine neuron function, survival and degeneration in Parkinson disease. Brain. 2020;143:3699–716.
Wani WY, Ouyang X, Benavides GA, Redmann M, Cofield SS, Shacka JJ, et al. O-GlcNAc regulation of autophagy and α-synuclein homeostasis; implications for Parkinson’s disease. Mol Brain. 2017;10:32.
Kumar A, Singh PK, Parihar R, Dwivedi V, Lakhotia SC, Ganesh S. Decreased O-linked GlcNAcylation protects from cytotoxicity mediated by huntingtin exon1 protein fragment. J Biol Chem. 2014;289:13543–53.
Tang B, Seredenina T, Coppola G, Kuhn A, Geschwind DH, Luthi-Carter R, et al. Gene expression profiling of R6/2 transgenic mice with different CAG repeat lengths reveals genes associated with disease onset and progression in Huntington’s disease. Neurobiol Dis. 2011;42:459–67.
Menalled LB, Kudwa AE, Miller S, Fitzpatrick J, Watson-Johnson J, Keating N, et al. Comprehensive behavioral and molecular characterization of a new knock-in mouse model of Huntington’s disease: zQ175. PLoS ONE. 2012;7:e49838.
Lange J, Wood-Kaczmar A, Ali A, Farag S, Ghosh R, Parker J, et al. Mislocalization of nucleocytoplasmic transport proteins in human Huntington’s disease PSC-derived striatal neurons. Front Cell Neurosci. 2021;15:742763.
Grima JC, Daigle JG, Arbez N, Cunningham KC, Zhang K, Ochaba J, et al. Mutant Huntingtin disrupts the nuclear pore complex. Neuron. 2017;94:93–107.e6.
Moll T, Shaw PJ, Cooper-Knock J. Disrupted glycosylation of lipids and proteins is a cause of neurodegeneration. Brain. 2020;143:1332–40.
Shan X, Vocadlo DJ, Krieger C. Reduced protein O-glycosylation in the nervous system of the mutant SOD1 transgenic mouse model of amyotrophic lateral sclerosis. Neurosci Lett. 2012;516:296–301.
Hsieh YL, Su FY, Tsai LK, Huang CC, Ko YL, Su LW, et al. NPGPx-mediated adaptation to oxidative stress protects motor neurons from degeneration in aging by directly modulating O-GlcNAcase. Cell Rep. 2019;29:2134–2143.e7.
Zhao MJ, Yao X, Wei P, Zhao C, Cheng M, Zhang D, et al. O-GlcNAcylation of TDP-43 suppresses proteinopathies and promotes TDP-43’s mRNA splicing activity. EMBO Rep. 2021;22:e51649.
Mueller T, Pinner A, Meador-Woodruff J. F199. O-Glcnac dysregulation in Schizophrenia cortex. Schizophr Bull. 2018;44:S298.
Stewart LT, Abiraman K, Chatham JC, McMahon LL. Increased O-GlcNAcylation rapidly decreases GABAAR currents in hippocampus but depresses neuronal output. Sci Rep. 2020;10:7494.
Cho Y, Hwang H, Rahman MA, Chung C, Rhim H. Elevated O-GlcNAcylation induces an antidepressant-like phenotype and decreased inhibitory transmission in medial prefrontal cortex. Sci Rep. 2020;10:6924.
Fan J, Zhong QL, Mo R, Lu CL, Ren J, Mo JW, et al. Proteomic profiling of astrocytic O-GlcNAc transferase-related proteins in the medial prefrontal cortex. Front Mol Neurosci. 2021;14:729975.
Lagerlöf O, Slocomb JE, Hong I, Aponte Y, Blackshaw S, Hart GW, et al. The nutrient sensor OGT in PVN neurons regulates feeding. Science. 2016;351:1293–6.
Dai CL, Gu JH, Liu F, Iqbal K, Gong CX. Neuronal O-GlcNAc transferase regulates appetite, body weight, and peripheral insulin resistance. Neurobiol Aging. 2018;70:40–50.
Andersson B, Tan EP, McGreal SR, Apte U, Hanover JA, Slawson C, et al. O-GlcNAc cycling mediates energy balance by regulating caloric memory. Appetite. 2021;165:105320.
Wheatley EG, Albarran E, White CW 3rd, Bieri G, Sanchez-Diaz C, Pratt K, et al. Neuronal O-GlcNAcylation improves cognitive function in the aged mouse brain. Curr Biol. 2019;29:3359–3369.e4.
Butler AA, Sanchez RG, Jarome TJ, Webb WM, Lubin FD. O-GlcNAc and EZH2-mediated epigenetic regulation of gene expression during consolidation of fear memories. Learn Mem. 2019;26:373–9.
Taylor EW, Wang K, Nelson AR, Bredemann TM, Fraser KB, Clinton SM, et al. O-GlcNAcylation of AMPA receptor GluA2 is associated with a novel form of long-term depression at hippocampal synapses. J Neurosci. 2014;34:10–21.